DK2376519T3 - TGR5-modulatorer og fremgangsmåde til anvendelse deraf - Google Patents
TGR5-modulatorer og fremgangsmåde til anvendelse derafInfo
- Publication number
- DK2376519T3 DK2376519T3 DK09760057.1T DK09760057T DK2376519T3 DK 2376519 T3 DK2376519 T3 DK 2376519T3 DK 09760057 T DK09760057 T DK 09760057T DK 2376519 T3 DK2376519 T3 DK 2376519T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- tgr5 modulators
- tgr5
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08169462 | 2008-11-19 | ||
PCT/US2009/065188 WO2010059853A1 (en) | 2008-11-19 | 2009-11-19 | Tgr5 modulators and method of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2376519T3 true DK2376519T3 (da) | 2014-02-03 |
Family
ID=41668454
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13192394.8T DK2698375T3 (da) | 2008-11-19 | 2009-11-19 | TGR5-modulatorer og fremgangsmåde til anvendelse deraf |
DK09760057.1T DK2376519T3 (da) | 2008-11-19 | 2009-11-19 | TGR5-modulatorer og fremgangsmåde til anvendelse deraf |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13192394.8T DK2698375T3 (da) | 2008-11-19 | 2009-11-19 | TGR5-modulatorer og fremgangsmåde til anvendelse deraf |
Country Status (23)
Country | Link |
---|---|
US (5) | US8114862B2 (da) |
EP (2) | EP2698375B1 (da) |
JP (5) | JP5535233B2 (da) |
KR (2) | KR101667436B1 (da) |
CN (2) | CN104370990A (da) |
AU (1) | AU2009316566B9 (da) |
BR (1) | BRPI0921983B8 (da) |
CA (1) | CA2744189C (da) |
DK (2) | DK2698375T3 (da) |
EA (2) | EA020140B1 (da) |
ES (2) | ES2663948T3 (da) |
HK (2) | HK1166327A1 (da) |
HU (1) | HUE039171T2 (da) |
IL (3) | IL212969A (da) |
LT (1) | LT2698375T (da) |
MX (1) | MX2011005295A (da) |
NO (1) | NO2698375T3 (da) |
PL (2) | PL2376519T3 (da) |
PT (2) | PT2698375T (da) |
SG (1) | SG10201400162QA (da) |
SI (1) | SI2698375T1 (da) |
WO (1) | WO2010059853A1 (da) |
ZA (1) | ZA201104077B (da) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2440680C (en) | 2001-03-12 | 2010-06-01 | Roberto Pellicciari | Steroids as agonists for fxr |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
JP5094384B2 (ja) | 2004-03-12 | 2012-12-12 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Fxrリガンドを使用する線維症の処置 |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
AU2008209566C1 (en) | 2007-01-19 | 2013-02-14 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
CA2732323C (en) | 2008-07-30 | 2017-06-27 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
JP5535233B2 (ja) * | 2008-11-19 | 2014-07-02 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Tgr5モジュレーターおよびその使用方法 |
CA2744817C (en) | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
CN102316889B (zh) | 2008-11-26 | 2014-11-26 | 萨蒂奥根制药公司 | 组合物及使用方法 |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
CA3047776C (en) | 2012-06-19 | 2022-10-18 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
CN104703585A (zh) | 2012-10-09 | 2015-06-10 | 宝洁公司 | 鉴定协同化妆品组合的方法 |
WO2014059008A1 (en) | 2012-10-09 | 2014-04-17 | The Procter & Gamble Company | Method of identifying or evaluating beneficial actives and compositions containing the same |
WO2014195950A1 (en) * | 2013-06-06 | 2014-12-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Bile acid-basic amino acid conjugates and uses thereof |
WO2014200349A1 (en) | 2013-06-13 | 2014-12-18 | Fast Forward Pharmaceutical B.V. | Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis. |
JP6621409B2 (ja) | 2013-11-22 | 2019-12-18 | ミナ セラピューティクス リミテッド | C/EBPα小分子活性化RNA組成物 |
DK3149019T3 (da) * | 2014-05-29 | 2020-02-17 | Bar Pharmaceuticals S R L | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme |
WO2016054208A1 (en) * | 2014-10-03 | 2016-04-07 | Mayo Foundation For Medical Education And Research | Targeting tgr5 to treat disease |
KR20170094184A (ko) * | 2014-11-06 | 2017-08-17 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
EP3221332B1 (en) | 2014-11-19 | 2019-04-24 | NZP UK Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
EA033603B1 (ru) | 2014-11-19 | 2019-11-08 | Nzp Uk Ltd | 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
US10301350B2 (en) | 2014-11-19 | 2019-05-28 | NZP UK Limited | 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal FXR modulators |
EA034739B1 (ru) | 2014-11-19 | 2020-03-16 | ЭнЗедПи ЮКей ЛИМИТЕД | 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
CN105985396A (zh) * | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
JP2018519246A (ja) * | 2015-04-28 | 2018-07-19 | ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド | コール酸誘導体、及びその製造方法及び医薬用途 |
US10800807B2 (en) | 2015-06-19 | 2020-10-13 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
KR20180043247A (ko) * | 2015-06-19 | 2018-04-27 | 인터셉트 파마슈티컬즈, 인크. | Tgr5 조절제 및 이를 사용하는 방법 |
CN108350020A (zh) * | 2015-09-24 | 2018-07-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
MA42339A1 (fr) * | 2015-10-07 | 2019-01-31 | Intercept Pharmaceuticals Inc | Modulateurs du récepteur farnésoïde x |
CN106008639B (zh) * | 2016-03-11 | 2019-01-08 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
JP6968821B2 (ja) | 2016-04-13 | 2021-11-17 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 癌を治療する方法 |
GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
WO2018005794A2 (en) * | 2016-07-01 | 2018-01-04 | Venenum Biodesign Llc | Novel non-systemic tgr5 agonists |
WO2018222701A1 (en) * | 2017-05-30 | 2018-12-06 | Intercept Pharmaceuticals, Inc. | Treatment of renal diseases with a bile acid derivative |
CN109021056B (zh) * | 2017-06-09 | 2021-03-09 | 博瑞生物医药(苏州)股份有限公司 | 法尼酯x受体激动剂 |
KR20200031145A (ko) | 2017-07-24 | 2020-03-23 | 인터셉트 파마슈티컬즈, 인크. | 동위원소 표지된 담즙산 유도체 |
WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
US20220096495A1 (en) * | 2019-02-04 | 2022-03-31 | Intercept Pharmaceuticals, Inc. | Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative |
CN116925168A (zh) * | 2019-08-23 | 2023-10-24 | 深圳云合医药科技合伙企业(有限合伙) | 胆汁酸衍生物及其组合物和应用 |
IL291985A (en) | 2019-10-07 | 2022-06-01 | Kallyope Inc | gpr119 agonists |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
EP4172162A1 (en) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Ampk activators |
KR20220004451A (ko) * | 2020-07-03 | 2022-01-11 | 연세대학교 산학협력단 | 지방간 질환의 예방 또는 치료를 위한 약학적 조성물 |
CN113774142A (zh) * | 2021-10-11 | 2021-12-10 | 北京化工大学 | Tgr5在制备治疗肠癌药物及诊断性试剂盒中的应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3366932D1 (en) | 1982-07-29 | 1986-11-20 | Lehner Ag | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
IT1206112B (it) | 1983-04-29 | 1989-04-14 | Lehner Ag | Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
IT1212835B (it) | 1983-08-18 | 1989-11-30 | Lehner Ag | Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
US4892868A (en) * | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
IT1196377B (it) * | 1984-12-21 | 1988-11-16 | Lehner Ag | Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche |
IT1223313B (it) | 1987-10-20 | 1990-09-19 | Gipharmex Spa | Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono |
IT1229570B (it) | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
US5175320A (en) | 1989-04-17 | 1992-12-29 | Giuliani S.P.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
DE69018592T2 (de) | 1989-12-13 | 1995-10-05 | Mitsubishi Chem Corp | Pyrazolylacrylsäure-Derivate, verwendbar als systemische Fungiziden in Pflanzen- und Materialschutz. |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
US5689791A (en) | 1996-07-01 | 1997-11-18 | Xerox Corporation | Electrically conductive fibers |
CN1230114A (zh) | 1996-07-12 | 1999-09-29 | 史密丝克莱恩比彻姆有限公司 | Leptine抵抗的新疗法 |
US6008237A (en) | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
EP1053227B1 (en) | 1998-01-29 | 2008-11-05 | Amgen Inc. | Ppar-gamma modulators |
EP1137940A4 (en) | 1998-10-23 | 2004-06-02 | Glaxo Group Ltd | METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS |
AU2389100A (en) | 1998-12-23 | 2000-07-12 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
WO2000040965A1 (en) | 1999-01-07 | 2000-07-13 | Tularik, Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
DE60029029T2 (de) | 1999-03-26 | 2007-06-14 | City Of Hope, Duarte | Screenen nach FXR-Rezeptormodulatoren |
US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
EP1473042B1 (en) | 1999-03-26 | 2006-06-21 | City of Hope | Screening for FXR receptor modulators |
US6906057B1 (en) | 1999-06-11 | 2005-06-14 | Allergan, Inc. | Methods for modulating FXR receptor activity |
JP2003501477A (ja) | 1999-06-11 | 2003-01-14 | アラーガン・セイルズ・インコーポレイテッド | Fxr受容体活性を調節する方法 |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
AU1215701A (en) | 1999-10-22 | 2001-05-08 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
AU2001246905A1 (en) | 2000-04-12 | 2001-10-23 | Takeda Chemical Industries Ltd. | Novel g protein-coupled receptor protein and dna thereof |
US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
US20020119958A1 (en) | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
CA2440680C (en) | 2001-03-12 | 2010-06-01 | Roberto Pellicciari | Steroids as agonists for fxr |
EP1378749A4 (en) | 2001-04-12 | 2005-05-11 | Takeda Pharmaceutical | SCREENING METHOD |
US20070010562A1 (en) | 2001-08-13 | 2007-01-11 | Ulrike Bauer | Nr1h4 nuclear receptor binding compounds |
EP1423113A4 (en) | 2001-08-13 | 2007-04-18 | Phenex Pharmaceuticals Ag | NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS |
ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
US20030144360A1 (en) | 2001-11-19 | 2003-07-31 | Allergan Sales, Inc. | Composition and method for modulating BAR/FXR receptor activity |
AU2003225903A1 (en) | 2002-03-21 | 2003-10-08 | Curagen Corporation | Methods of using farnesoid x receptor (fxr) agonists |
CA2482195A1 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
TWI242543B (en) | 2002-06-19 | 2005-11-01 | Availvs Corp | Artificial stone wall material |
ITMI20021532A1 (it) | 2002-07-12 | 2004-01-12 | Roberto Pellicciari | Composti chimici |
JP2006515838A (ja) | 2002-11-22 | 2006-06-08 | スミスクライン ビーチャム コーポレーション | ファルネソイドx受容体アゴニスト |
CA2514547A1 (en) | 2003-01-28 | 2004-08-12 | Takeda Pharmaceutical Company Limited | Receptor agonists |
EP1696910A4 (en) | 2003-09-26 | 2009-12-09 | Smithkline Beecham Corp | COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS |
EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
JP5094384B2 (ja) | 2004-03-12 | 2012-12-12 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Fxrリガンドを使用する線維症の処置 |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
SI2040713T1 (sl) | 2006-06-27 | 2014-11-28 | Intercept Pharmaceuticals, Inc. | Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR |
EP1947108A1 (en) | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
AU2008209566C1 (en) * | 2007-01-19 | 2013-02-14 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
JP5535233B2 (ja) * | 2008-11-19 | 2014-07-02 | インターセプト ファーマシューティカルズ, インコーポレイテッド | Tgr5モジュレーターおよびその使用方法 |
-
2009
- 2009-11-19 JP JP2011537624A patent/JP5535233B2/ja not_active Expired - Fee Related
- 2009-11-19 CN CN201410532890.0A patent/CN104370990A/zh active Pending
- 2009-11-19 EA EA201170714A patent/EA020140B1/ru unknown
- 2009-11-19 US US12/622,123 patent/US8114862B2/en active Active
- 2009-11-19 KR KR1020117014037A patent/KR101667436B1/ko active IP Right Grant
- 2009-11-19 ES ES13192394T patent/ES2663948T3/es active Active
- 2009-11-19 EP EP13192394.8A patent/EP2698375B1/en active Active
- 2009-11-19 PT PT131923948T patent/PT2698375T/pt unknown
- 2009-11-19 PL PL09760057T patent/PL2376519T3/pl unknown
- 2009-11-19 EA EA201400258A patent/EA030681B1/ru not_active IP Right Cessation
- 2009-11-19 CA CA2744189A patent/CA2744189C/en active Active
- 2009-11-19 MX MX2011005295A patent/MX2011005295A/es active IP Right Grant
- 2009-11-19 ES ES09760057.1T patent/ES2458168T3/es active Active
- 2009-11-19 DK DK13192394.8T patent/DK2698375T3/da active
- 2009-11-19 SG SG10201400162QA patent/SG10201400162QA/en unknown
- 2009-11-19 HU HUE13192394A patent/HUE039171T2/hu unknown
- 2009-11-19 BR BRPI0921983A patent/BRPI0921983B8/pt active IP Right Grant
- 2009-11-19 PT PT97600571T patent/PT2376519E/pt unknown
- 2009-11-19 KR KR1020167028159A patent/KR101789960B1/ko active IP Right Grant
- 2009-11-19 EP EP09760057.1A patent/EP2376519B1/en active Active
- 2009-11-19 LT LTEP13192394.8T patent/LT2698375T/lt unknown
- 2009-11-19 AU AU2009316566A patent/AU2009316566B9/en active Active
- 2009-11-19 PL PL13192394T patent/PL2698375T3/pl unknown
- 2009-11-19 SI SI200931820T patent/SI2698375T1/sl unknown
- 2009-11-19 NO NO13192394A patent/NO2698375T3/no unknown
- 2009-11-19 CN CN200980154713.0A patent/CN102325784B/zh active Active
- 2009-11-19 DK DK09760057.1T patent/DK2376519T3/da active
- 2009-11-19 WO PCT/US2009/065188 patent/WO2010059853A1/en active Application Filing
-
2011
- 2011-05-18 IL IL212969A patent/IL212969A/en active IP Right Grant
- 2011-06-01 ZA ZA2011/04077A patent/ZA201104077B/en unknown
- 2011-12-07 US US13/313,689 patent/US8445472B2/en active Active
-
2012
- 2012-07-17 HK HK12106982.3A patent/HK1166327A1/xx not_active IP Right Cessation
-
2013
- 2013-04-26 US US13/871,492 patent/US9650409B2/en active Active
-
2014
- 2014-04-22 JP JP2014088019A patent/JP2014159456A/ja not_active Withdrawn
-
2015
- 2015-06-10 HK HK15105499.8A patent/HK1205132A1/xx unknown
- 2015-08-14 JP JP2015160141A patent/JP2015232020A/ja active Pending
-
2016
- 2016-03-29 IL IL244812A patent/IL244812B/en active IP Right Grant
-
2017
- 2017-04-07 US US15/482,107 patent/US20180016295A1/en not_active Abandoned
- 2017-04-19 JP JP2017083045A patent/JP2017132803A/ja not_active Withdrawn
-
2018
- 2018-03-27 JP JP2018059922A patent/JP2018100304A/ja not_active Withdrawn
-
2019
- 2019-02-12 IL IL264796A patent/IL264796B/en active IP Right Grant
-
2020
- 2020-11-09 US US17/092,612 patent/US20210269473A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2376519T3 (da) | TGR5-modulatorer og fremgangsmåde til anvendelse deraf | |
DK2337568T3 (da) | Fremgangsmåder og midler til blødvævsteknologi | |
DK2147315T3 (da) | Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf | |
DK2342858T3 (da) | Fremgangsmåde og apparat til tilvejebringelse af redundansversioner | |
DK3614595T3 (da) | Fremgangsmåde og indretning til forbedrede statusrapporter | |
DK2307459T3 (da) | Notch1-receptorbindende midler og fremgangsmåder til anvendelse deraf | |
BRPI0912934A2 (pt) | aparelho e método | |
BRPI0916735A2 (pt) | moduladores de tgr5 e métodos de uso do mesmo | |
DK3509324T3 (da) | Balancerede armaturindretninger og fremgangsmåder til at høre | |
BRPI0921992A2 (pt) | moduladores tgr5 e métodos de uso destes | |
DK2271933T3 (da) | System og fremgangsmåde til cellekarakterisering | |
DK2127419T3 (da) | Fremgangsmåde og anordning til tilvejebringelse af effektiv diskontinuerlig kommunikation | |
BRPI0910713A2 (pt) | método e aparelhos | |
DK2346551T3 (da) | Cylinderampul og kanylesystem til denne | |
DK2248385T3 (da) | Fremgangsmåde og indretning til at prioritere logiske kanaler | |
BRPI0808684A2 (pt) | moduladores de tgr5 e métodos de uso destes | |
DK2304568T3 (da) | Fremgangsmåde og system til fordelt raid-implementering | |
DK2331238T3 (da) | Fremgangsmåde og enhed til fotosyntesestøttet co2-bortskaffelse | |
DK2337837T3 (da) | Alpha-amylase-blandinger og fremgangsmåder til anvendelse heraf | |
DK3211126T3 (da) | Fremgangsmåder til dannelse og screening af dna-kodede biblioteker | |
DK2309938T3 (da) | Kryokirurgiske systemer og fremgangsmåder til anvendelse heraf | |
DK2358669T3 (da) | Alpha-keto-persyrer og fremgangsmåder til fremstilling og anvendelse heraf | |
NO20076533L (no) | Fremgangsmåte og system for klokkedriftskompensering | |
DK2270818T3 (da) | Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten | |
DK2310357T3 (da) | Kaliumionkanalmodulatorer og anvendelser deraf |